Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
André, Marc
[Clear All Filters]
2024
Camus V
,
Thieblemont C
,
Gaulard P
,
Cheminant M
,
Casasnovas R-O
,
Ysebaert L
,
Damaj GLaurent
,
Guidez S
,
Pica GMatteo
,
Kim WSeog
, et al.
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
J Clin Oncol. 2024:JCO2301687.
PubMed
Google Scholar
2023
Belada D
,
Kopeckova K
,
Burgues JMiguel Ber
,
Stevens D
,
André M
,
Persona EPerez
,
Pichler P
,
Staber PB
,
Trneny M
,
Duell J
, et al.
Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: Phase 1b First-MIND study.
Blood. 2023.
PubMed
Google Scholar
Duell J
,
Abrisqueta P
,
André M
,
Gaidano G
,
Gonzales-Barca E
,
Jurczak W
,
Kalakonda N
,
Liberati AMarina
,
Maddocks KJ
,
Menne T
, et al.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study.
Haematologica. 2023.
PubMed
Google Scholar
2021
Zoellner A-K
,
Unterhalt M
,
Stilgenbauer S
,
Hübel K
,
Thieblemont C
,
Metzner B
,
Topp M
,
Truemper L
,
Schmidt C
,
Bouabdallah K
, et al.
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol. 2021;8(9):e648-e657.
PubMed
Google Scholar
Bachy E
,
Camus V
,
Thieblemont C
,
Sibon D
,
Casasnovas R-O
,
Ysebaert L
,
Damaj G
,
Guidez S
,
Pica GMatteo
,
Kim WSeog
, et al.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
J Clin Oncol. 2021:JCO2101815.
PubMed
Google Scholar
2020
Salles G
,
Duell J
,
Barca EGonzález
,
Tournilhac O
,
Jurczak W
,
Liberati AMarina
,
Nagy Z
,
Obr A
,
Gaidano G
,
André M
, et al.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol. 2020.
PubMed
Google Scholar
2013
Van Den Neste E
,
Casasnovas O
,
André M
,
Touati M
,
Senecal D
,
Edeline V
,
Stamatoullas A
,
Fornecker L
,
Deau B
,
Gastinne T
, et al.
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.
Haematologica. 2013;98(8):1185-95.
PubMed
Google Scholar